

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following potential equality issues were identified during the scoping process:

- Inequality of access to LDL-apheresis due to high set up costs for treatment and few established centres with appropriate expertise
- Injection only treatment which will exclude people who will not accept injection based therapies, including many from ethnic minority groups.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

These issues could not be addressed through a Technology Appraisal and therefore do not need to be addressed by Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 31/07/2015